News

Molecular markers in the blood shown to be predictive of severe COVID-19 outcomes resulting from SARS-CoV-2 coronavirus infection have been identified in a study.

A decade-long experiment found that lower nitrogen levels in soil promoted release of carbon dioxide from soils under high levels of atmospheric carbon dioxide, and could therefore contribute to furthering rising atmospheric greenhouse gases and climate change.

A new study has found that patients treated with immunotherapies may suffer from more than one immune-related side-effect.

Southampton-led research has shown that implementing point-of-care testing in hospitals to diagnose influenza can lead to better treatment and faster recovery for patients.

Scientists found in a study that an imbalance in the gut bacterial community can cause a reduction in metabolites, leading to depressing behavior.

Researchers have discovered two genes involved in the molecular processes of antiviral immunity and inflammation within the lungs.

Researchers from Skoltech and their colleagues from Russia and the US have described two new, compact Cas9 nucleases, the cutting components of CRISPR-Cas systems, that will potentially expand the Cas9 toolbox for genome editing.

Neuroscientists have found no significant links between COVID-19 and the potentially paralysing and sometimes fatal neurological condition Guillain-Barré syndrome (GBS). The study looks at links at both a molecular and epidemiological level, finding no increased rate of GBS in 2020 and also no molecular evidence to suggest the SARS-CoV-2 virus could drive GBS.

Scientists have developed a new rapid detection method of nucleic acids from SARS-CoV-2, using hybrid capture fluorescence immunoassay.

The U.S. Food and Drug Administration issued the first emergency use authorization (EUA) for a vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 16 years of age and older. The emergency use authorization allows the Pfizer-BioNTech COVID-19 Vaccine to be distributed in the U.S.